Scientific Programme – Saturday, November 26

08:30 – 10:05   Session V 
08:30 E. O’Neill Back-to-basics II: Introduction in radiobiology | Edward O’Neill
09:15 C. Müller OP16 Can We Profit from the Auger Electron Emission of Terbium-161 Using Somatostatin Receptor Antagonists?
09:27 D. Niculae OP17 Comparative study on 64Cu production on variable energy cyclotrons TR-19 (ACSI) /KIUBE (IBA) using solid and liquid targets
09:39 F. Barbaro OP18 natCr(p,x) or natV(α,x)? Dosimetric assessments at comparison for high-purity 52gMn PET tracer production
09:51 U.A. Kvitastein OP19 Production and Separation of the PET-radionuclide Ti-45 from a Liquid nat-Sc Target for Ligand Complexation

10:15 – Meet the Author poster session with coffee break 

10:35 – 12:20   Session VI 
10:35 R. Eychenne Invited Lecture 4: Alpha particle therapy – are we there yet
11:20 M. Spahn OP20 Second generation Al18F-labeled D-amino acid based peptide for CXCR4 targeted molecular imaging
11:32 T. S. Zavvar OP21 Preclinical testing and automated synthesis of [177Lu]-labelled DOTA-MGS5 for application in CCK2R-targeted therapy
11:44 K. Lu OP22 Synthesis and evaluation of two 18F-labeled Lys-ureido-Aad derivatives for imaging prostate-specific membrane antigen expression with positron emission tomography
11:56 F. Krutzek OP23 Synthesis and Biological Evaluation of Chelator-Based Small Molecule PET-Radiotracers for Imaging of PD-L1
12:08 S. Pandey OP24 Affinity of 68Ga-DOTAGA-IAC towards αvβ3 integrin receptor and application in imaging tumor angiogenesis

12:20 – Lunch

13:45 – 15:18   Session VII 
13:45 C. Groot Invited Lecture 5: Tau PET imaging: the clinical challenges
14:30 C. Vaccarin OP25 Development of ACE-selective radioligands as molecular tools to investigate the imbalance of the renin-angiotensin-aldosterone system during Covid-19.
14:42 L. Meléndez-Alafort OP26 Comparison of preclinical dosimetric studies of 177Lu-scFvD2B, 177Lu-PSMA-617 and 177Lu-iPSMA
14:54 N. Lepareur OP27 Preliminary results of the Lip-Re1 phase 1 trial: pharmacokinetics study of 188Re-SSS/Lipiodol for HCC treatment
15:06 J. Pougoue Ketchemen OP28 Theranostic potential of [67Cu]Cu-NOTA-trastuzumab against HER2 positive breast cancer.

15:18 – Coffee Break / Poster Viewing Session 

16:30 – 17:30   Session VIII
16:30 Debate: GMP, The Italian vs Austrian approach | Clemens Decristoforo, Marianne Patt, Petra Kolenc-Peitl, Sergio Todde
17:00 T. Kroon, E. Pel Pharmacopoeia Corner,